Skip to content

Effect of Short Course of Glucocorticoid in Patients With Diabetes Mellitus(DM) Type 2

Glucocorticoid Effects in Patients With DM Type 2

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03661684
Enrollment
10
Registered
2018-09-07
Start date
2016-06-03
Completion date
2017-07-01
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hyperglycemia Steroid-induced

Keywords

Diabetes, Glucocorticoids, Hyperglycemia

Brief summary

Participants will receive prednisone 40 mg for 3 days. 75 g oral glucose tolerance test (OGTT), insulin and C-peptide will be measured on day 1 (before prednisone) and day 3 (after prednisone). Also capillary glucose values will be obtained during and after the period of prednisone intake.

Detailed description

On their scheduled day, participants will be instructed to come to the clinic after an overnight fast of a minimum of 8 hours (subjects can drink water). The participants will be asked to refrain from drinking alcohol for a period of 24 hours before the study days and to not perform strenuous exercise for a period of 48 hours before the study days. The participants will be directed to avoid alcohol and strenuous exercise for the duration of the study. On days 1 and 3 of the study period, participants will be checked into the clinic. A physical examination, including height, weight and waist circumference, and finger-stick glucose will be performed. A 75-g OGTT will be performed with venous samples for measurement of glucose, insulin and C-peptide levels obtained at 0, 30 and 60 minutes starting immediately after the ingestion of the 75 g glucose solution. After samples are collected on day 1, participants will be administered their first dose of steroid, prednisone 40 mg, and be given a packet of two additional doses for the rest of the study period. The investigators may only give 1 additional dose to them and have the participants take the last dose in clinic on day 3 two hours before the OGTT. Subjects will take prednisone 40 mg once daily for three days to be consumed around 8:00am on days 2 and 3. This dose was chosen as a typical high-dose glucocorticoid regimen. On the third day, the participants will again visit the clinic after an overnight fast of a minimum 8 hours and undergo a physical examination and OGTT just as on day 1. Participants will be instructed to check pre-prandial (before breakfast, lunch and dinner), and bed time (around 10:00 pm) blood glucose (BG) levels and to record all values for a total of five days (three days while on prednisone and for two days after the second study visit). A member of the study staff will call each participant daily around 7:00 pm to obtain BG values. Compliance with the study protocol will be assessed at this time as well. Any subject not compliant with study medications will be excluded from the study.

Interventions

DRUGPrednisone

40 mg po q day of Prednisone for 3 days

Sponsors

Cook County Health
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Two groups. Condition group and Control group, both receiving the investigated medication using the same protocol

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Experimental Group Inclusion Criteria: 1. Males or non-pregnant females between the ages of 18-50 years being followed in the Diabetes Center. 2. Type 2 Diabetes for ≤ 1 year and only on metformin 3. BMI 24.0-35.0 kg/ m2 4. HBA1c ≤ 9.0%

Exclusion criteria

1. Patients on any other antidiabetes medication. 2. Patients with impaired renal function (estimated Glomerular Filtration Rate (GFR) less than 60 ml/min based on results from Cerner). 3. Patient who have received glucocorticoid therapy within six months of study. 4. Patients who do shift work. 5. Blood glucose level ≥ 250 mg/dl on finger-stick at clinic visit. 6. Signs or symptoms of infection. Control Group Inclusion Criteria: 1. Males or non-pregnant females between the ages of 18-50 years in good physical health as determined by medical history, physical examination, and screening blood tests 2. Normoglycemia defined by fasting plasma glucose \< 5.6 mmol/L (or 100 mg/dL) and 2h glucose \<7.8 mmol/L (or 140 mg/dL) after a 75 g OGTT 3. BMI: 22.0 - 28.0 kg/m2

Design outcomes

Primary

MeasureTime frameDescription
AUC for glucose during OGTTThroughout the course of 3 daysComparison of the Area under the curve (AUC) of the OGTT for glucose values at 60 and 120 throughout the course of 3 days

Secondary

MeasureTime frameDescription
HOMA indexAt day 1 and at day 3Comparison of Homeostatic model assessment (HOMA) index before and after receiving the prednisone dose (at day 1 and at day 3)
AUC for Insulin during OGTTThroughout the course of 3 daysComparison of the Area under the curve of the OGTT for glucose values at 60 and 120 minutes throughout the course of 3 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026